Newron Pharmaceuticals — Pivotal enrolment complete; FDA review continues

Newron Pharmaceuticals has completed ENIGMA-TRS 1 enrolment in treatment-resistant schizophrenia (TRS), with 618 patients randomised and pivotal 12-week data expected in Q127.

Keller Group — CMD establishes medium-term ambitions

Keller’s CMD set out targets of 5–7% organic revenue CAGR, a c 7% operating margin, c 30% ROCE and c £800m cumulative free cash flow over 2026–30, alongside dividend cover of 2.5–3.5x.

OSE Immunotherapeutics — CombiTED bolsters Tedopi’s clinical potential

OSE Immunotherapeutics (OSE) has reported positive top-line results from the FoRT sponsored Phase II CombiTED study of its cancer vaccine Tedopi in metastatic non-small cell lung cancer (NSCLC).

SCHMID — Positive order momentum continues

SCHMID’s Q3 business updates highlight strong demand for its equipment, as PCB and advanced packaging manufacturers expand capacity to support growing demand for AI-related technology.

Recce Pharmaceuticals — Blinded data bodes well for upcoming R327G Phase III data release

A review of blinded study data from Recce’s ongoing Phase III registrational study of the RECCE 327 topical gel formulation (R327G) for the treatment of diabetic foot infections (DFIs) indicates...

Starpharma — Taking control of Petalion’s next phase

Starpharma has increased its interest in Petalion Therapeutics to 66%, from 22.5%, taking control of its fibroblast activation protein (FAP) targeted oncology programme

JPMorgan European Discovery Trust — Managers building on their positive record

JPMorgan European Discovery Trust (JEDT) had a change of managers at the beginning of March 2024, which has been beneficial for the trust’s performance

Datatec — H127 underlying EPS up at least 52% y-o-y

Datatec’s H127 trading update confirmed that Westcon and Logicalis International delivered very strong financial performances in H127

OncoZenge — Phase III execution brings pivotal readout into focus

OncoZenge is entering a value-defining period with BupiZenge, its Phase III-stage sustained-release lozenge for oral mucositis (OM) pain in head and neck cancer

Primary Health Properties — JV agreed: Focus on growth

Amoeba — Commercial ambitions set and financing progresses

Amoéba’s H126 results outlined a strategic update to its medium-term growth ambitions following first biocontrol sales in the period.

Smiths News — Telegraphing another contract win

Smiths News has announced that it has secured a new long-term exclusive contract with Telegraph Media Group Holdings Limited (TMG), publishers of the Daily Telegraph and Sunday Telegraph.

discoverIE Group — Upgrading on strong H127 trading

discoverIE confirmed that the positive order momentum it has seen since Q426 continued through H127.

MindMaze Therapeutics — Progress on the neurotherapeutics roll-out

MindMaze Therapeutics is continuing the commercial roll-out of its digital neurotherapeutic platform, with a heightened focus on its home-based offerings, which is also supported by existing US...

Baillie Gifford US Growth Trust — Vote to save winning public/private US strategy

Baillie Gifford US Growth Trust (USA) gives investors exposure to exceptional US growth businesses across both public and private markets.

One and one Green Technologies — Copper strength offsets aluminium disruption

One and one Green Technologies’ (YDDL’s) H126 results showed continued strength in copper alloy

In the chair with bp’s Emeka Emembolu: AI a massive opportunity for bp

Emeka Emembolu, executive vice president, technology, at bp, speaks to Neil Shah, executive director and market strategist at Edison Group, in the third interview in Edison’s series on bp.

Corero Network Security — Momentum in orders continues into Q326

Corero’s Q326 update provides further evidence that the investments in its product portfolio and sales channels are delivering.

Utilico Emerging Markets Trust — Opportune time to consider unique EM exposure

Utilico Emerging Markets Trust (UEM) offers investors a differentiated, lower beta (c 0.6) exposure to above-average growth in emerging markets via a diversified portfolio of high-quality utility and...

Pan American Silver — From M&A-led scale to organic silver growth

Pan American Silver (PAAS) has grown into the largest independent primary silver producer alongside a sizeable gold business following a series of well-timed acquisitions and subsequent portfolio...